Sanofi (SNY) Other Accumulated Expenses (2016 - 2026)

Sanofi has disclosed Other Accumulated Expenses across 11 years of filings, most recently posting $8.0 billion for Q2 2026.

• In Q2 2026, Other Accumulated Expenses fell 1.18% year-over-year to $8.0 billion; the TTM figure through Jun 2026 stood at $8.0 billion (down 1.18% YoY), while the FY2025 annual figure was $7.8 billion, down 10.96% from the prior year.
• Other Accumulated Expenses came in at $8.0 billion for Q2 2026 at Sanofi, up from $7.8 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $8.9 billion in Q2 2024 to a low of $6.5 billion in Q4 2022.
• Average Other Accumulated Expenses over 5 years is $7.8 billion, with a median of $8.0 billion recorded in 2026.
• Year-over-year, Other Accumulated Expenses retreated 22.01% in 2022 and gained 26.43% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $6.5 billion in 2022, then advanced by 26.43% to $8.2 billion in 2023, then grew by 5.77% to $8.7 billion in 2024, then decreased by 9.81% to $7.8 billion in 2025, then increased by 2.02% to $8.0 billion in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $8.0 billion in Q2 2026, $7.8 billion in Q4 2025, and $8.1 billion in Q2 2025.